Cocrystal Pharma (NASDAQ:COCP) Issues Earnings Results

Cocrystal Pharma (NASDAQ:COCP) posted its quarterly earnings results on Thursday. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.06), FiscalAI reports. The business had revenue of $0.10 million during the quarter, compared to the consensus estimate of $0.23 million.

Cocrystal Pharma Stock Up 1.4%

Shares of NASDAQ COCP traded up $0.01 on Friday, hitting $1.11. The company had a trading volume of 14,364 shares, compared to its average volume of 1,023,306. Cocrystal Pharma has a 12-month low of $0.76 and a 12-month high of $2.67. The firm has a market capitalization of $15.38 million, a P/E ratio of -1.53 and a beta of 1.43. The business has a 50 day moving average of $0.99 and a two-hundred day moving average of $1.10.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 8th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Hedge Funds Weigh In On Cocrystal Pharma

An institutional investor recently bought a new stake in Cocrystal Pharma stock. DRW Securities LLC purchased a new position in Cocrystal Pharma, Inc. (NASDAQ:COCP) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma as of its most recent SEC filing. Hedge funds and other institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.